13F HOLDINGS REPORT
BAKER BROS. ADVISORS LP
Quarter ended Q2 2024 · Filed August 14, 2024 · Accession 0001104659-24-089606
Total Value
$7.83B
Positions
95
Other Managers
0
Confidential Omitted
No
Holdings (95)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Incyte Corporation | INCY | 30,738,524 | $1.86B | 23.81% |
| 2 | BeiGene, Ltd. | BEIGF | 10,568,897 | $1.51B | 19.27% |
| 3 | ACADIA Pharmaceuticals Inc. | ACAD | 42,877,916 | $696.8M | 8.90% |
| 4 | Madrigal Pharmaceuticals, Inc. | MDGL | 1,974,590 | $553.2M | 7.07% |
| 5 | Revolution Medicines, Inc. | RVMDW | 7,569,090 | $293.8M | 3.75% |
| 6 | Rhythm Pharmaceuticals, Inc. | RYTM | 6,398,365 | $262.7M | 3.36% |
| 7 | Insmed Incorporated | INSM | 3,576,038 | $239.6M | 3.06% |
| 8 | Bicycle Therapeutics plc | BCYC | 9,399,960 | $190.3M | 2.43% |
| 9 | Summit Therapeutics Inc. | SMMT | 23,222,222 | $181.1M | 2.31% |
| 10 | Kymera Therapeutics, Inc. | KYMR | 5,995,928 | $179.0M | 2.29% |
| 11 | Edgewise Therapeutics, Inc. | EWTX | 5,840,059 | $105.2M | 1.34% |
| 12 | Alkermes plc | ALKS | 4,181,751 | $100.8M | 1.29% |
| 13 | Insmed Incorporated | INSM | 42,850,000 | $90.4M | 1.16% |
| 14 | Replimune Group, Inc. | REPL | 10,045,336 | $90.4M | 1.16% |
| 15 | Denali Therapeutics Inc. | DNLI | 3,731,695 | $86.6M | 1.11% |
| 16 | AbCellera Biologics Inc. | ABCL | 27,525,640 | $81.5M | 1.04% |
| 17 | Nurix Therapeutics, Inc. | NRIX | 3,882,125 | $81.0M | 1.04% |
| 18 | Immatics N.V. | IMTX | 6,443,398 | $74.9M | 0.96% |
| 19 | Entrada Therapeutics, Inc. | TRDA | 4,865,819 | $69.3M | 0.89% |
| 20 | Ultragenyx Pharmaceutical Inc. | RARE | 1,466,547 | $60.3M | 0.77% |
| 21 | Stoke Therapeutics, Inc. | STOK | 4,368,443 | $59.0M | 0.75% |
| 22 | Insmed Incorporated | INSM | 32,887,000 | $56.2M | 0.72% |
| 23 | Kiniksa Pharmaceuticals International, plc | G52694109 | 2,818,323 | $52.6M | 0.67% |
| 24 | Immunocore Holdings plc | IMCR | 1,515,318 | $51.4M | 0.66% |
| 25 | argenx SE | ARGX | 111,904 | $48.1M | 0.61% |
| 26 | Kodiak Sciences Inc. | KOD | 17,310,490 | $40.7M | 0.52% |
| 27 | Xenon Pharmaceuticals Inc. | XENE | 993,679 | $38.7M | 0.50% |
| 28 | Prelude Therapeutics Inc. | PRLD | 10,123,824 | $38.6M | 0.49% |
| 29 | IDEAYA Biosciences, Inc. | IDYA | 1,062,123 | $37.3M | 0.48% |
| 30 | Cerus Corporation | CERS | 19,477,339 | $34.3M | 0.44% |
| 31 | Sera Prognostics, Inc. | SERA | 5,434,399 | $32.2M | 0.41% |
| 32 | Krystal Biotech, Inc. | KRYS | 169,934 | $31.2M | 0.40% |
| 33 | Celcuity Inc. | CELC | 1,874,978 | $30.7M | 0.39% |
| 34 | Roivant Sciences Ltd. | ROIV | 2,798,716 | $29.6M | 0.38% |
| 35 | IGM Biosciences, Inc. | 449585108 | 4,090,316 | $28.1M | 0.36% |
| 36 | Cerevel Therapeutics Holdings, Inc. | 15678U128 | 683,588 | $28.0M | 0.36% |
| 37 | Akero Therapeutics, Inc. | 00973Y108 | 1,097,082 | $25.7M | 0.33% |
| 38 | Dyne Therapeutics, Inc. | DYN | 672,096 | $23.7M | 0.30% |
| 39 | Alumis Inc. | ALMS | 1,562,500 | $20.8M | 0.27% |
| 40 | Monte Rosa Therapeutics, Inc. | GLUE | 4,916,095 | $18.4M | 0.23% |
| 41 | Merus N.V. | N5749R100 | 300,000 | $17.8M | 0.23% |
| 42 | Neurogene Inc. | NGNE | 456,015 | $16.6M | 0.21% |
| 43 | TScan Therapeutics, Inc. | TCRX | 2,784,792 | $16.3M | 0.21% |
| 44 | Sana Biotechnology, Inc. | SANA | 2,380,949 | $13.0M | 0.17% |
| 45 | Immunovant, Inc. | IMVT | 464,718 | $12.3M | 0.16% |
| 46 | Xencor, Inc. | XNCR | 545,431 | $10.3M | 0.13% |
| 47 | Neumora Therapeutics, Inc. | NMRA | 1,034,600 | $10.2M | 0.13% |
| 48 | Fate Therapeutics, Inc. | FATE | 2,997,772 | $9.8M | 0.13% |
| 49 | 2seventy bio, Inc. | 901384107 | 2,497,526 | $9.6M | 0.12% |
| 50 | Biomea Fusion, Inc. | BMEA | 2,108,949 | $9.5M | 0.12% |
| 51 | Celldex Therapeutics, Inc. | CLDX | 247,644 | $9.2M | 0.12% |
| 52 | Taysha Gene Therapies, Inc. | TSHA | 4,004,756 | $9.0M | 0.11% |
| 53 | Athira Pharma, Inc. | 04746L104 | 3,153,807 | $8.4M | 0.11% |
| 54 | Verve Therapeutics, Inc. | 92539P101 | 1,691,530 | $8.3M | 0.11% |
| 55 | Relay Therapeutics, Inc. | RLAY | 1,160,117 | $7.6M | 0.10% |
| 56 | Mirum Pharmaceuticals, Inc. | MIRM | 190,476 | $6.5M | 0.08% |
| 57 | Tango Therapeutics, Inc. | TNGX | 750,000 | $6.4M | 0.08% |
| 58 | KALA BIO, Inc. | KALA | 891,335 | $6.3M | 0.08% |
| 59 | DBV Technologies S.A. | DBVTF | 7,307,131 | $5.9M | 0.07% |
| 60 | Design Therapeutics, Inc. | DSGN | 1,695,294 | $5.7M | 0.07% |
| 61 | Contineum Therapeutics, Inc. | CTNM | 312,500 | $5.5M | 0.07% |
| 62 | Praxis Precision Medicines, Inc. | PRAX | 131,533 | $5.4M | 0.07% |
| 63 | CRISPR Therapeutics AG | CRSP | 100,000 | $5.4M | 0.07% |
| 64 | Prime Medicine, Inc. | PRME | 1,028,466 | $5.3M | 0.07% |
| 65 | Centessa Pharmaceuticals plc | CNTA | 549,212 | $5.0M | 0.06% |
| 66 | HOOKIPA Pharma Inc. | HOOK | 8,128,151 | $4.8M | 0.06% |
| 67 | Sagimet Biosciences Inc. | SGMT | 1,381,898 | $4.7M | 0.06% |
| 68 | Crinetics Pharmaceuticals, Inc. | CRNX | 103,927 | $4.7M | 0.06% |
| 69 | Talis Biomedical Corporation | 87424L207 | 508,323 | $4.4M | 0.06% |
| 70 | Alector, Inc. | ALEC | 927,264 | $4.2M | 0.05% |
| 71 | Opthea Limited | OPTEY | 2,173,622 | $4.2M | 0.05% |
| 72 | Skye Bioscience, Inc. | SKYE | 500,000 | $4.0M | 0.05% |
| 73 | Vaxcyte, Inc. | PCVX | 48,885 | $3.7M | 0.05% |
| 74 | Arcturus Therapeutics Holdings Inc. | ARCT | 151,329 | $3.7M | 0.05% |
| 75 | Generation Bio Co. | 37148K100 | 1,206,957 | $3.4M | 0.04% |
| 76 | Enliven Therapeutics, Inc. | ELVN | 114,833 | $2.7M | 0.03% |
| 77 | Leap Therapeutics, Inc. | CYPH | 1,172,175 | $2.3M | 0.03% |
| 78 | Adaptimmune Therapeutics plc | ADTI | 2,343,695 | $2.3M | 0.03% |
| 79 | Mersana Therapeutics, Inc. | 59045L106 | 1,086,115 | $2.2M | 0.03% |
| 80 | Century Therapeutics, Inc. | IPSC | 797,460 | $2.0M | 0.03% |
| 81 | NewAmsterdam Pharma Company N.V. | NAMSW | 96,827 | $1.9M | 0.02% |
| 82 | Sage Therapeutics, Inc. | 78667J108 | 171,026 | $1.9M | 0.02% |
| 83 | vTv Therapeutics, Inc. | VTVT | 97,314 | $1.7M | 0.02% |
| 84 | Compass Therapeutics, Inc. | CMPX | 1,557,630 | $1.6M | 0.02% |
| 85 | Protara Therapeutics, Inc. | TARA | 536,832 | $1.1M | 0.01% |
| 86 | Aerovate Therapeutics, Inc. | 008064107 | 628,939 | $1.0M | 0.01% |
| 87 | Pfizer Inc. | PFE | 35,000 | $979,300 | 0.01% |
| 88 | Achilles Therapeutics plc | 00449L102 | 1,108,767 | $903,645 | 0.01% |
| 89 | Aligos Therapeutics, Inc. | ALGS | 2,076,400 | $726,740 | 0.01% |
| 90 | PMV Pharmaceuticals, Inc. | PMVP | 322,024 | $521,679 | 0.01% |
| 91 | BioCryst Pharmaceuticals, Inc. | BCRX | 75,778 | $468,308 | 0.01% |
| 92 | Acrivon Therapeutics, Inc. | ACRV | 52,885 | $306,733 | 0.00% |
| 93 | Foghorn Therapeutics Inc. | FHTX | 45,027 | $258,905 | 0.00% |
| 94 | Tyra Biosciences, Inc. | TYRA | 10,607 | $169,606 | 0.00% |
| 95 | Surrozen, Inc. | SRZNW | 833,333 | $13,833 | 0.00% |